A new report by XploreMR studies the growth drivers, trends, restraints, and highlights of the global kidney cancer diagnostics market. Presenting exclusive insights into the market from 2017 to 2022, the report projects that the market will witness notable growth during the forecast period. The two major types of kidney cancer are transitional cell carcinoma (CTC) and renal cell carcinoma (RCC) has long term effects and can be fatal if not diagnosed early. On this premise, the need for effective kidney cancer diagnostics has been on a rise over the years. The growth of the market is predominantly attributed to the increasing adoption of advanced therapies, such as cytokine-based and nephrectomy-based treatments, rising incidence of kidney cancer among the geriatric population, and growing spending on research and development activities. Moreover, the introduction of technologically advanced tests with high precision and accuracy will further fuel the growth of the kidney cancer diagnostics market.

Burgeoning Number of Diagnoses Every Year Escalates Demand for Testing Technologies

According to the Global Cancer Observatory (GLOBOCAN), the incidence of kidney cancer has increased to 4.5 out of 100,000 in 2018, and the statistics of the American Cancer Society reveal that over 73,820 cases of kidney cancer have been diagnosed in 2019, with the number of mortalities surging past 14,770 in the same year. The soaring number of cancer cases is increasing the demand for effective kidney cancer diagnostics across the world. The surging demand is also being complemented by the technological developments in the landscape of diagnosis and treatment management. Over the years, there have been numerous discoveries and studies in the renal mass biopsy, minimally-invasive thermal ablation, and active surveillance, that have yielded effective results. Furthermore, targeted systemic therapies for metastatic kidney cancer have proven effective in survival and progression. Likewise, partial nephrectomy therapy is gaining prominence as a standard diagnosis-based surgical management option for low-stage masses. Such developments will continue to propel the demand for kidney cancer diagnostics. In addition to conventional diagnostic technologies, such as MRI and CT scans, the advancements in medical technology - which are aiding in decelerating the growth of tumors - are paving the way for effective treatments, further contributing to the market growth.

Presence of Strong Healthcare Architecture Abets North America to Lead Regional Landscape

North America will continue to lead the kidney cancer diagnostic market, backed by an increasing number of cases in the region. Moreover, the presence of strong healthcare architecture increased private and government spending on R&D, and high levels of awareness among the population are continuing to increase regional growth. Likewise, Europe is also one of the leading regions, owing to the high presence of the geriatric population. On the other hand, Asia Pacific is set for impressive growth, owing to a high prevalence of renal cancer and increasing awareness among the population.